Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging

Erica Andreozzi, Peter Wang, Anthony Valenzuela, Chuqiao Tu, Fredric A Gorin, Marc Dhenain, Angelique Louie

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Solid lipid nanoparticles (SLNs) have recently emerged as nontoxic, versatile alternatives to traditional carriers (liposomes, polymeric nanoparticles) for drug delivery. Because SLNs are composed of a solid lipid core, they offer significant protection against chemical degradation of their drug cargo and offer the potential for controlled release. SLNs also hold promise for use as targeted agents and multimodal imaging agents. Here we report the synthesis and characterization of SLNs loaded with gadolinium (1,4,7,10-tetraazacyclododecane)-1,4,7,10-tetraacetate (Gd-DOTA) in order to produce a new category of stable T1-weighted (T1w) magnetic resonance imaging (MRI) contrast agents. Systematically varying components in the SLN synthesis, we demonstrated an increase in Gd-DOTA incorporation and an increase in longitudinal relaxivity (r1) through optimizing the amount of surfactant (Span 80) in the "oil" phase. These highly monodisperse SLNs confirm stable loading of Gd-DOTA and a stable size distribution (∼150 nm) over time in aqueous solution. Relaxivity measurements (1.4T, 37 C) demonstrate that the r1 of Gd-DOTA does not strongly decrease following encapsulation in SLNs, demonstrating an advantage over liposomes. These Gd-loaded SLNs demonstrate enhanced contrast in vivo at 7T using T1w MRI and in the future can be loaded with other cargo (hydrophilic or hydrophobic) to enable functionality with other imaging modalities such as optical or positron emission tomography.

Original languageEnglish (US)
Pages (from-to)1455-1467
Number of pages13
JournalBioconjugate Chemistry
Volume24
Issue number9
DOIs
StatePublished - Sep 18 2013

Fingerprint

Magnetic resonance
Nanoparticles
Lipids
Magnetic Resonance Imaging
Imaging techniques
Liposomes
Multimodal Imaging
gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
Positron emission tomography
Gadolinium
Drug delivery
Encapsulation
Surface-Active Agents
Pharmaceutical Preparations
Positron-Emission Tomography
Contrast Media
Oils
Surface active agents
Degradation

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Organic Chemistry
  • Pharmaceutical Science
  • Biomedical Engineering
  • Pharmacology

Cite this

Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging. / Andreozzi, Erica; Wang, Peter; Valenzuela, Anthony; Tu, Chuqiao; Gorin, Fredric A; Dhenain, Marc; Louie, Angelique.

In: Bioconjugate Chemistry, Vol. 24, No. 9, 18.09.2013, p. 1455-1467.

Research output: Contribution to journalArticle

Andreozzi, E, Wang, P, Valenzuela, A, Tu, C, Gorin, FA, Dhenain, M & Louie, A 2013, 'Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging', Bioconjugate Chemistry, vol. 24, no. 9, pp. 1455-1467. https://doi.org/10.1021/bc300605f
Andreozzi, Erica ; Wang, Peter ; Valenzuela, Anthony ; Tu, Chuqiao ; Gorin, Fredric A ; Dhenain, Marc ; Louie, Angelique. / Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging. In: Bioconjugate Chemistry. 2013 ; Vol. 24, No. 9. pp. 1455-1467.
@article{8119836457674376bc8b235c50f4828f,
title = "Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging",
abstract = "Solid lipid nanoparticles (SLNs) have recently emerged as nontoxic, versatile alternatives to traditional carriers (liposomes, polymeric nanoparticles) for drug delivery. Because SLNs are composed of a solid lipid core, they offer significant protection against chemical degradation of their drug cargo and offer the potential for controlled release. SLNs also hold promise for use as targeted agents and multimodal imaging agents. Here we report the synthesis and characterization of SLNs loaded with gadolinium (1,4,7,10-tetraazacyclododecane)-1,4,7,10-tetraacetate (Gd-DOTA) in order to produce a new category of stable T1-weighted (T1w) magnetic resonance imaging (MRI) contrast agents. Systematically varying components in the SLN synthesis, we demonstrated an increase in Gd-DOTA incorporation and an increase in longitudinal relaxivity (r1) through optimizing the amount of surfactant (Span 80) in the {"}oil{"} phase. These highly monodisperse SLNs confirm stable loading of Gd-DOTA and a stable size distribution (∼150 nm) over time in aqueous solution. Relaxivity measurements (1.4T, 37 C) demonstrate that the r1 of Gd-DOTA does not strongly decrease following encapsulation in SLNs, demonstrating an advantage over liposomes. These Gd-loaded SLNs demonstrate enhanced contrast in vivo at 7T using T1w MRI and in the future can be loaded with other cargo (hydrophilic or hydrophobic) to enable functionality with other imaging modalities such as optical or positron emission tomography.",
author = "Erica Andreozzi and Peter Wang and Anthony Valenzuela and Chuqiao Tu and Gorin, {Fredric A} and Marc Dhenain and Angelique Louie",
year = "2013",
month = "9",
day = "18",
doi = "10.1021/bc300605f",
language = "English (US)",
volume = "24",
pages = "1455--1467",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Size-stable solid lipid nanoparticles loaded with Gd-DOTA for magnetic resonance imaging

AU - Andreozzi, Erica

AU - Wang, Peter

AU - Valenzuela, Anthony

AU - Tu, Chuqiao

AU - Gorin, Fredric A

AU - Dhenain, Marc

AU - Louie, Angelique

PY - 2013/9/18

Y1 - 2013/9/18

N2 - Solid lipid nanoparticles (SLNs) have recently emerged as nontoxic, versatile alternatives to traditional carriers (liposomes, polymeric nanoparticles) for drug delivery. Because SLNs are composed of a solid lipid core, they offer significant protection against chemical degradation of their drug cargo and offer the potential for controlled release. SLNs also hold promise for use as targeted agents and multimodal imaging agents. Here we report the synthesis and characterization of SLNs loaded with gadolinium (1,4,7,10-tetraazacyclododecane)-1,4,7,10-tetraacetate (Gd-DOTA) in order to produce a new category of stable T1-weighted (T1w) magnetic resonance imaging (MRI) contrast agents. Systematically varying components in the SLN synthesis, we demonstrated an increase in Gd-DOTA incorporation and an increase in longitudinal relaxivity (r1) through optimizing the amount of surfactant (Span 80) in the "oil" phase. These highly monodisperse SLNs confirm stable loading of Gd-DOTA and a stable size distribution (∼150 nm) over time in aqueous solution. Relaxivity measurements (1.4T, 37 C) demonstrate that the r1 of Gd-DOTA does not strongly decrease following encapsulation in SLNs, demonstrating an advantage over liposomes. These Gd-loaded SLNs demonstrate enhanced contrast in vivo at 7T using T1w MRI and in the future can be loaded with other cargo (hydrophilic or hydrophobic) to enable functionality with other imaging modalities such as optical or positron emission tomography.

AB - Solid lipid nanoparticles (SLNs) have recently emerged as nontoxic, versatile alternatives to traditional carriers (liposomes, polymeric nanoparticles) for drug delivery. Because SLNs are composed of a solid lipid core, they offer significant protection against chemical degradation of their drug cargo and offer the potential for controlled release. SLNs also hold promise for use as targeted agents and multimodal imaging agents. Here we report the synthesis and characterization of SLNs loaded with gadolinium (1,4,7,10-tetraazacyclododecane)-1,4,7,10-tetraacetate (Gd-DOTA) in order to produce a new category of stable T1-weighted (T1w) magnetic resonance imaging (MRI) contrast agents. Systematically varying components in the SLN synthesis, we demonstrated an increase in Gd-DOTA incorporation and an increase in longitudinal relaxivity (r1) through optimizing the amount of surfactant (Span 80) in the "oil" phase. These highly monodisperse SLNs confirm stable loading of Gd-DOTA and a stable size distribution (∼150 nm) over time in aqueous solution. Relaxivity measurements (1.4T, 37 C) demonstrate that the r1 of Gd-DOTA does not strongly decrease following encapsulation in SLNs, demonstrating an advantage over liposomes. These Gd-loaded SLNs demonstrate enhanced contrast in vivo at 7T using T1w MRI and in the future can be loaded with other cargo (hydrophilic or hydrophobic) to enable functionality with other imaging modalities such as optical or positron emission tomography.

UR - http://www.scopus.com/inward/record.url?scp=84884409674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884409674&partnerID=8YFLogxK

U2 - 10.1021/bc300605f

DO - 10.1021/bc300605f

M3 - Article

VL - 24

SP - 1455

EP - 1467

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 9

ER -